Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
biomee™ is a line of biotech-derived topical skincare products developed by MC2 Therapeutics using their proprietary PAD (Polyaphron Dispersion) Technology™. The formulation is designed to provide relief for moderate to severe itch and dry skin associated with conditions such as chronic kidney disease-associated pruritus (CKD-aP), vulvar lichen sclerosus (VLS), and incontinence-associated dermatitis (IAD). The PAD Technology allows for ultra-pure formulations with extremely low emulsifier levels (less than 0.6%), which helps maintain the skin's natural microbiome and reduces irritation. The products utilize an encapsulation technology that provides sustained release of ingredients, adapting to the skin's pH and moisture levels to optimize barrier function and comfort. While currently marketed as over-the-counter (OTC) skincare, the formulation is also being evaluated in Phase 2 clinical development for specific medical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on biomee.